Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | IKBKB | O14920 | 13/20 | 0.37 |
| ▸ | CHUK | O15111 | 3/20 | 0.33 |
| ▸ | EPHA3 | P29320 | 3/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | TERT | O14746 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6485082 | 0.87 | SMN1; SMN2 (0.30) | SMN1; SMN2 | |
| SCHEMBL6641959 | 0.81 | IKBKB (0.36) | SMN1; SMN2IKBKBCHUKEPHA3PDGFRA | |
| SCHEMBL5448783 | 0.78 | ADORA3 (0.31) | — | |
| SCHEMBL6487409 | 0.76 | JAK1 (0.34) | — | |
| SCHEMBL6642545 | 0.68 | LPO (0.34) | — | |
| SCHEMBL6642225 | 0.67 | PADI4 (0.32) | — | |
| SCHEMBL6476378 | 0.66 | SMN1; SMN2 (0.37) | SMN1; SMN2IKBKB | |
| Hydrochloric Acid SCHEMBL7813040 | 0.64 | SMN1; SMN2 (0.60) | SMN1; SMN2TERT | |
| SCHEMBL5685695 | 0.63 | MAPT (0.42) | IKBKB | |
| SCHEMBL30742732 | 0.63 | MAPT (0.42) | IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4696376-A2 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | Topadur Pharma AG (CH) | 2026-02-18 | — | — | EP | disclosed |
| EP-3630769-B1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2025-07-02 | — | — | EP | disclosed |
| US-20240360136-A1 | DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2024-10-31 | — | — | US | disclosed |
| CN-118063458-A | Novel dual mode of action of soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | 托帕杜制药公司 | 2024-05-24 | — | — | CN | disclosed |
| US-11905293-B2 | Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | TOPADUR PHARMA AG (CH) | 2024-02-20 | — | — | US | disclosed |
| CN-110621676-B | Dual mode of action of soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | 托帕杜制药公司 | 2024-02-09 | — | — | CN | disclosed |
| US-20220073529-A1 | DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2022-03-10 | — | — | US | disclosed |
| US-20220073529-A1 | DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2022-03-10 | — | — | US | disclosed |
| US-11155558-B2 | Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | TOPADUR PHARMA AG (CH) | 2021-10-26 | — | — | US | disclosed |
| US-11155558-B2 | Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | TOPADUR PHARMA AG (CH) | 2021-10-26 | — | — | US | disclosed |
| US-20200181149-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2020-06-11 | — | — | US | disclosed |
| US-20200181149-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2020-06-11 | — | — | US | disclosed |
| EP-3630769-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | Topadur Pharma AG (CH) | 2020-04-08 | — | — | EP | disclosed |
| CN-110621676-A | Novel dual mode of action of soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | 托帕杜制药公司 | 2019-12-27 | — | — | CN | disclosed |
| WO-2018215433-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2018-11-29 | — | — | WO | disclosed |
| US-6962911-B2 | Pyrrolopyrimidinone derivatives, process of preparation and use | SK CHEMICALS CO., LTD. (KR) | 2005-11-08 | — | — | US | disclosed |
| EP-1257553-B1 | PYRROLOPYRIMIDINONE DERIVATIVES, PROCESS OF PREPARATION AND USE | SK CHEMICALS CO LTD (KR) | 2004-05-26 | — | — | EP | disclosed |
| US-20030171361-A1 | Pyrrolopyrimidinone derivatives, process of preparation and use | SK CHEMICALS CO., LTD. (KR) | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171361-A1 | Pyrrolopyrimidinone derivatives, process of preparation and use | CYP2C19, DHPS, SDHA | SMN1; SMN2 2323/4885IKBKB 2108/4885CHUK 1571/4885 |
| US-20220073529-A1 | DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE5A, PDE1A, PDE2A | SMN1; SMN2 960/4885IKBKB 1634/4885CHUK 731/4885 |
| US-11155558-B2 | Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | PDE7A, GNAO1, PDE3A | SMN1; SMN2 3706/4885IKBKB 2019/4885CHUK 1495/4885 |
| US-20200181149-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE7A, PDE3A, PDE9A | SMN1; SMN2 3301/4885IKBKB 2105/4885CHUK 1457/4885 |
| US-11905293-B2 | Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | PDE5A, PDE1A, PDE2A | SMN1; SMN2 960/4885IKBKB 1634/4885CHUK 731/4885 |
| US-20240360136-A1 | DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE5A, PDE1A, PDE2A | SMN1; SMN2 960/4885IKBKB 1634/4885CHUK 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.